Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab

BACKGROUND: Pembrolizumab is a checkpoint inhibitor that targets the programmed cell death-1 receptor (PD-1) and has shown to be effective against several malignancies, including lung cancer. However, life-threatening immune-related adverse events can result from these immunotherapy treatments. Case...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuenca, John A., Laserna, Andres, Reyes, María P., Nates, Joseph L., Botz, Gregory H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132356/
https://www.ncbi.nlm.nih.gov/pubmed/32274219
http://dx.doi.org/10.1155/2020/8671530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132356/
https://www.ncbi.nlm.nih.gov/pubmed/32274219
http://dx.doi.org/10.1155/2020/8671530

Ejemplares similares